MindRank has shared the skinny on its oral GLP-1 receptor agonist, publishing data from a Chinese phase 2b obesity trial that suggests efficacy is in the same ballpark as Eli Lilly’s orforglipron.

Three (3.1%) subjects measured a subtherapeutic dose (<2.5 mL) with the syringe. In general, participants measured less than the intended dose with the oral syringe and more than the intended dose ...

Despite these findings, the majority of adults believed that the oral syringe and dosing cup would measure an accurate dose. CLICK HERE for more information about this journal.

Orforglipron is the first oral small molecule (non-peptide) glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial.

CHICAGO &mdash; Orforglipron, a novel nonpeptide, small molecule oral GLP-1, reduced HbA1c at 40 weeks for patients with type 2 diabetes, according to results of the phase 3 ACHIEVE-1 trial ...

Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and ...

Fluoxetine Oral Solution, USP 20 mg/5 mL is available by prescription and should only be used under the guidance of a licensed healthcare provider to ensure safe and effective treatment.

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in ...

Twenty years ago, Shakira dropped her sixth studio album, "Fijación Oral, Vol. 1." Billboard editors rank all 10 songs, from worst to best.

Quiver AI Summary Kymera Therapeutics announced encouraging results from a Phase 1 trial of KT-621, its once-daily oral STAT6 degrader for treating Th2-driven allergic diseases.

In TODAY.com's Expert Tip of the Day, a heart surgeon reveals the common oral hygiene product that may be hurting your cardiovascular health and what to use instead.

A phase 1 FIH study of novel oral SERD FWD1802 in patients with ER+/HER2- unresectable locally advanced or metastatic breast cancer with or without ESR1 mutations.. If you have the appropriate ...